Article

Dr. Brenda Motheral Discusses Employer and Health Plan Roles in Specialty Pharmacy Management

Brenda Motheral, BPharm, MBA, PhD, Executive Director, PBMI, addresses the gap between what plan sponsors say is important and what is actually being monitored within specialty pharmacy. She notes the issues sponsors have on monitoring spending, as well as the problems pharmacy benefit managers face when monitoring medication adherence with specialty patients.

Brenda Motheral, BPharm, MBA, PhD, Executive Director, PBMI, addresses the gap between what plan sponsors say is important and what is actually being monitored within specialty pharmacy. She notes the issues sponsors have on monitoring spending, as well as the problems pharmacy benefit managers face when monitoring medication adherence with specialty patients.

Related Videos
Screenshot of an interview with Evangelia Vlachou, MD
Aditya Bardia, MD, MPH, FASCO, medical oncologist, UCLA Health
Screenshot of an interview with Barry Goy, MD
Gladys Antelo Allen
Dr Michael Bernstein
Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine
Debra Patt, MD, PhD, MBA, MPH
Jeff Stark, MD, vice president, head of medical immunology, UCB.
Mikkael Sekeres, MD
Kim Newcomer, director of volunteers, Colorectal Cancer Alliance
Related Content
Dr Michael Bernstein
February 13th 2025

Understanding TB Symptoms, Spread, Treatment Amid Kansas City Outbreak

Brooke McCormick Michael A. Bernstein, MD
In part 2 of this interview, Michael A. Bernstein, MD, highlights the need for prolonged antibiotics and strong public health measures to combat tuberculosis (TB) at both the individual and population levels.
Telemedicine’s Evolution and Expanding Access to Obesity, Specialty Care
February 11th 2025

Telemedicine’s Evolution and Expanding Access to Obesity, Specialty Care

Maggie L. Shaw George Jones
George Jones of UpScript Health discusses telemedicine's evolution from basic e-prescribing to real-time video consultations, expanding treatment beyond primary care.
Christian Ruff, MD
February 11th 2025

Abelacimab Shows Potential to Shift the Standard of Care in AFib

Kyle Munz Christian Ruff, MD Dan Bloomfield, MD
Results from the AZALEA-TIMI 71 phase 2 trial showed great promise for abelacimab to transform care for high-risk patients with atrial fibrillation.
Managed Care Cast Logo
February 4th 2025

Politics vs Science: The Future of US Public Health

Maggie L. Shaw Perry N. Halkitis, PhD, MS, MPH
On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Terra Wonsettler, PharmD, MBA | Image credit: Evolent
February 7th 2025

Evolent’s Wonsettler Sees Outcomes-Based Reimbursement as “A Healthy Tool”

Interview by Mary Caffrey Terra Wonsettler, PharmD, MBA
Terra Wonsettler, PharmD, MBA, vice president of pharmacy for Evolent, discusses the recent HHS OIG report that stemmed from the 2021 FDA approval of aducanumab (Aduhelm) and use of the accelerated approval pathway.
Jeff Stark, MD, UCB
February 6th 2025

Dr Jeff Stark: New Bimzelx Dose Offers Simplicity and Choice

Maggie L. Shaw Jeff Stark, MD
On October 14, 2024, the FDA approved a 320-mg single dose of bimekizumab-bkzx (Bimzelx; UCB) in a 2-mL prefilled syringe and autoinjector; both forms are now commercially available in the US.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo